Condition Directory

Prostate Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 29, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

3912

Shown on this page

Current sort

How Prostate Cancer studies are organized in the registry

Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.

Terms that often appear in related listings

castration-resistant CRPC hormone-sensitive biochemical recurrence

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 313–324 of 3,912 matching trials for Prostate Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Prostate Cancer Screening
Interventions: MRI, ExactVu; Device
Lead sponsor: University of Alberta; Other
Eligibility: 50 Years to 70 Years · Male only
Enrollment: 1,284 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Los Angeles, California • Dallas, Texas

Conditions: Prostatic Neoplasms
Interventions: JNJ-98768111; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Sarasota, Florida • Grand Rapids, Michigan • West Valley City, Utah

Conditions: Prostatic Neoplasms
Interventions: Radiotherapy, LHRHa, Apalutamide; Radiation · Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 13
States / cities: Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more

Conditions: Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Interventions: Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Androgen Deprivation Therapy (ADT), Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 2,517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 44
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 36 more

Conditions: Prostate Carcinoma
Interventions: Behavioral Intervention, Biospecimen Collection, Electronic Health Record Review, Genetic Counseling, Genetic Testing, Interview, Survey Administration; Behavioral · Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Genomic and Histological Evaluation; Genetic
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 35 Years to 85 Years · Male only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Prostate Cancer
Interventions: CARE-PC Web-Based Application; Behavioral
Lead sponsor: Vivek Narayan; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Carcinoma
Interventions: Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Magnetic Resonance Whole Body Diffusion-Weighted Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Castration-Sensitive Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8
Interventions: Pharmacotherapy Discontinuation, Follow-Up, Questionnaire Administration, Quality-of-Life Assessment; Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 326
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 234 more

Conditions: Prostate Cancer
Interventions: BPX-601; Genetic
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Atlanta, Georgia • Hackensack, New Jersey • Portland, Oregon

Conditions: Metastatic Castration Resistant Prostate Cancer, mCRPC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, mCRPC or Advanced/Metastatic Solid Tumors, mCRPC, Metastatic Castration Resistant Prostate Cancer, Neoplasms Prostate, Neoplasms of Prostate
Interventions: FX-111; Drug
Lead sponsor: Flare Therapeutics Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 6 more

About this Prostate Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Prostate Cancer clinical trials

How Prostate Cancer studies are organized in the registry

Filter and sort this condition

Live official records

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

Non-Invasive Biomarkers in Prostate Cancer Disease Management

The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study

Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

About this Prostate Cancer clinical trials directory page